Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.750
+0.110 (2.37%)
At close: Nov 22, 2024, 4:00 PM
4.900
+0.150 (3.16%)
After-hours: Nov 22, 2024, 7:30 PM EST
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $10.01M in the twelve months ending September 30, 2024, down -61.22% year-over-year. In the year 2023, Relay Therapeutics had annual revenue of $25.55M with 1,749.82% growth.
Revenue (ttm)
$10.01M
Revenue Growth
-61.22%
P/S Ratio
62.75
Revenue / Employee
$30,978
Employees
323
Market Cap
795.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.12B |
Pacira BioSciences | 694.96M |
Avanos Medical | 681.50M |
Cytek Biosciences | 201.21M |
Avid Bioservices | 142.36M |
Prothena Corporation | 133.35M |
Cronos Group | 111.23M |
AbCellera Biologics | 32.96M |
RLAY News
- 16 days ago - Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 23 days ago - Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - GlobeNewsWire
- 2 months ago - Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion - Seeking Alpha
- 2 months ago - Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations - Seeking Alpha
- 2 months ago - GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 2 months ago - Relay Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market - Benzinga
- 2 months ago - This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga